论文部分内容阅读
全替换型人工心脏(TAH)于1957年由Akutsn和kelff首先开创。当时用氯化乙烯制成袋状TAH,用于实验狗身上,存活1时半。1969年Cooley首次用隔膜状TAH做心脏移植前的替换术,运行血流达64小时。至今用隔膜状JARVIK型TAH已治疗60例晚期心功不全患者。现在长期使用TAH已能维持患者的循环,有的已长达622日,可是多数患者在使用人工心脏后发生了脑栓塞。最近对心脏移植前用TAH替换,多在50天内。由于心脏的排斥反应,在欧美用TAH过渡来维持循环,最长者达396日。用JARVIK型TAH过渡者约50％心脏移植术后得以存活,其中康复后工作者约80％。术后脑栓塞过去一直认为是TAH本身引起的,现已查明为TAH和生体接头及安装的人工瓣周形成血栓而引起脑栓塞。所以改良设计,采用提高机
The fully-replaceable artificial heart (TAH) was first pioneered in 1957 by Akutsn and kelff. At that time made of vinyl chloride bag TAH, used for experimental dogs who survive 1:30. In 1969, Cooley first performed septal TAH as a replacement before heart transplantation, running blood for 64 hours. To date, 60 patients with advanced cardiac insufficiency have been treated with membranous JARVIK TAH. Long-term use of TAH has been able to maintain the patient’s circulation, some as long as 622 days, but most patients with cerebral embolism after the use of the artificial heart. Recently replaced with TAH before heart transplantation, more than 50 days. Due to cardiac rejection, TAH transition in Europe and America to maintain the cycle, the longest reached 396 days. About 50% of heart transplants with JARVIK-type TAH survived, with approximately 80% of post-rehabilitation workers. Postoperative cerebral embolism has historically been thought to be caused by TAH itself and has now been identified as causing thrombus formation in thrombus caused by TAH and biopsy and installed prosthetic aortic valves. So improve the design, use to improve the machine